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Background:  Major vascular complications (VC) remain an important issue after transfemoral transcatheter aortic valve implantation 
(TF-TAVI). Previous studies demonstrated that major VC were frequent with first-generation of transcatheter heart valves (THV) and were 
associated with higher 30-day mortality using the Valve Academic Research Consortium (VARC-1) criteria. The definition of VC has been 
recently revised leading to the VARC-2 consensus document. Therefore, the aim of our study was to evaluate the incidence of major VC 
after TF-TAVI using second generation of THV and the impact on 30-day mortality according to VARC-2 criteria.
methods:  From 2010 and 2013, 368 consecutive patients underwent TF-TAVI with the Edwards Sapien XT prosthesis using exclusively 
local anesthesia and percutaneous closure device in our department. The 30-day rates of major VC and effect on 30-day mortality were 
assessed according to the VARC-1 and VARC -2 definitions.
results:  Twenty-four (6.5%) and 58 (15.8%) patients had major VC according to the VARC-1 and VARC-2 definitions, respectively. Among 
patients with major VC, percutaneous closure device failure and access-site hematoma were the most frequent modes of presentation. 
Using VARC-1 criteria, major VC were significantly associated with higher rate of 30-day mortality [16.7% vs. 5.2%; OR = 3.57, 95% CI 
(1.12-12.5); p=0.03]. Using VARC-2 criteria, 30-day mortality remained higher in patients with major VC, although the difference was no 
more significant [27.3% vs. 15.0%; OR= 2.12, 95% CI (0.79-5.67); p=0.134].
conclusion:  The incidence of major VC remains frequent after TF-TAVI using second generation of THV. As compared to VARC-1 criteria, 
the incidence of MVC after TF-TAVI is higher using VARC-2 definition but is no more significantly associated with significant increase of 30-
day mortality. Further studies are warranted to confirm our results in a larger population.
